CCL22 and mycosis fungoides: For example, as we described above, since topical bexarotene [12] or imiquimod [22] reduces the production of CCL22, leading to suppression of the recruitment of CTCL cells and regulatory T cells in the lesional skin of MF, either combined with surface molecular-targeted therapy described in next section might be suitable to complete the reduction of CTCL.